As antibody–drug conjugates have become a very important modality for cancer therapy,
many site-specific conjugation approaches have been developed for generating …

Antibody–drug conjugates (ADCs) have developed rapidly in recent decades. However, it is
complicated to map out a perfect ADC that requires optimization of multiple parameters …

Heterobifunctional compounds that direct the ubiquitination of intracellular proteins in a
targeted manner via co-opted ubiquitin ligases have enormous potential to transform the …

The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and
related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin …

Chimeric molecules which effect intracellular degradation of target proteins via E3 ligase-
mediated ubiquitination (eg, PROTACs) are currently of high interest in medicinal chemistry …

The vast majority of currently marketed drugs rely on small molecules with an 'occupancy-
driven'mechanism of action (MOA). Therefore, the efficacy of these therapeutics depends on …

Targeting selective estrogen subtype receptors through typical medicinal chemistry
approaches is based on occupancy-driven pharmacology. In occupancy-driven …

Breast cancer is the most common cancer suffered by female, and the second highest cause
of cancer-related death among women worldwide. At present, hormone therapy is still the …

Abstract Antibody-Drug Conjugates (ADCs) are a rapidly growing class of anticancer agents
comprising a small molecule cytotoxin and a monoclonal antibody (mAb). A covalent linker …

The subject matter described herein is directed to methods of preparing certain antibody-
drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein …